CITATION REPORT List of articles citing

Bacterial translocation (BT) in cirrhosis

DOI: 10.1002/hep.20632 Hepatology, 2005, 41, 422-33.

Source: https://exaly.com/paper-pdf/38329770/citation-report.pdf

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
583	Bacterial infections in patients with cirrhosis. 2005 , 68, 447-51		20
582	Endogenous opioids and liver disease. 2006 , 41, 1-11		5
581	Toll-like receptor signaling in the liver. 2006 , 130, 1886-900		335
580	The intestinal flora and bacterial infection in cirrhosis. <i>Journal of Hepatology</i> , 2006 , 45, 744-57	13.4	87
579	Syndrome hpatorfial. 2006 , 1, 1-7		
578	Bibliography. Current world literature. Liver and biliary tract. 2006 , 22, 305-39		
577	The management of severe alcoholic liver disease and variceal bleeding in the intensive care unit. 2006 , 12, 171-7		2
576	Hypertonic saline enhances host defense to bacterial challenge by augmenting Toll-like receptors. 2006 , 34, 1758-68		42
575	Portal hypertension. 2006 , 22, 254-62		6
574	Bibliography. Current world literature. Pathogenesis and immune response. 2006 , 19, 298-311		
573	Bacteriophage translocation. 2006 , 46, 313-9		149
572	Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. <i>Hepatology</i> , 2006 , 43, 673-81	11.2	218
571	The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. <i>Hepatology</i> , 2006 , 44, 633-9	11.2	78
570	[Elevated concentrations of fecal calprotectin in patients with liver cirrhosis]. 2006, 131, 1930-4		12
569	Bacterial infection-related morbidity and mortality in cirrhosis. 2007 , 102, 1510-7		179
568	Infections in Patients With End-stage Liver Disease. 2007 , 41, 403-11		78
567	Intestinal barrier dysfunction in developing liver cirrhosis: An in vivo analysis of bacterial translocation. 2007 , 37, 6-12		20

probiotiques Et Autres Pathologies Digestives : Perspectives. **2007**, 42, 60-66

565	Cirrhotic cardiomyopathy. 2007 , 39, 507-15	40
564	Endotoxemia during liver transplantation. 2007 , 13, 1616-7	2
563	Pathogenesis of hepatic encephalopathy: the tumour necrosis factor-alpha theory. 2007 , 37, 291-304	63
562	Relationship between circulating levels of tumour necrosis factor-alpha and Child-Pugh scores in liver cirrhosis. 2007 , 61, 519; author reply 520	1
561	[Infection and variceal bleeding in cirrhosis]. 2007, 31, 27-38	4
560	Bacterial DNA induces the complement system activation in serum and ascitic fluid from patients with advanced cirrhosis. 2007 , 27, 438-44	34
559	Epidemiology and outcome of primary community-acquired bacteremia in adult patients. 2007 , 26, 453-7	21
558	Pathogenetic background for treatment of ascites and hepatorenal syndrome. 2008 , 2, 416-28	37
557	Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. <i>Hepatology</i> , 2008 , 47, 978-85	128
556	Toll-like receptors and adaptor molecules in liver disease: update. <i>Hepatology</i> , 2008 , 48, 322-35 11.2	544
555	Uncoupling of sympathetic nervous system and hypothalamic-pituitary-adrenal axis in cirrhosis. 2008 , 23, 1901-8	23
554	Probiotics: where are they going next? New and emerging areas of research. 2008, 33, 359-363	4
553	Nutrition in end-stage liver disease: principles and practice. 2008 , 134, 1729-40	115
552	Evaluation and management of end-stage liver disease in children. 2008, 134, 1741-51	57
551	Portal hypertension and its complications. 2008 , 134, 1715-28	256
550	Hemodynamic effects of substance P and its receptor antagonist RP67580 in anesthetized rats with carbon tetrachloride-induced cirrhosis. 2008 , 43, 328-33	4
549	Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. <i>Journal of Hepatology</i> , 2008 , 48, 945-51	200

548	Is bacterial DNA a surrogate marker of bacterial translocation in cirrhosis?. <i>Journal of Hepatology</i> , 2008 , 49, 145-6; author reply 146-7	13.4	3
547	A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. 2008 , 375, 210-4		33
546	Brain edema in acute liver failure. 2008 , 24, 99-114, ix		33
545	The management of ascites and hyponatremia in cirrhosis. 2008 , 28, 43-58		66
544	Genomics can advance the potential for probiotic cultures to improve liver and overall health. 2008 , 14, 1376-81		15
543	Probiotics and liver disease. 2008 , 42 Suppl 2, S80-4		33
542	. 2008,		2
541	Review: Rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy. 2008 , 149, JC5		
540	Influence of the Escherichia coli Nissle 1917 strain on complications of the chronic experimental liver damage. 2008 , 52, 121-129		1
539	The Enteric Flora in Intestinal Failure. 167-184		2
538	Effect of honey on bacterial translocation and intestinal morphology in obstructive jaundice. 2008 , 14, 3410-5		21
537	Functional Disaccharides. 2009 ,		
536	Mesenteric microcirculatory dysfunctions and translocation of indigenous bacteria in a rat model of strangulated small bowel obstruction. 2009 , 64, 911-9		26
535	Analysis of monocyte chemotactic protein-1 gene polymorphism in patients with spontaneous bacterial peritonitis. 2009 , 15, 5558-62		18
534	Alterations in mechanical properties of mesenteric resistance arteries in experimental portal hypertension. 2009 , 297, G849-57		17
533	[Probiotics in gastrointestinal disorders]. 2009 , 150, 883-94		O
532	Increased plasma carbon monoxide in patients with viral cirrhosis and hyperdynamic circulation. 2009 , 104, 891-7		18
531	A positive breath hydrogen test does not predict the occurrence of a spontaneous bacterial peritonitis in cirrhotic patients with ascites. 2009 , 79, 252-8		3

(2009-2009)

530	portal hypertension in cd39-null mice. 2009 , 297, G306-11	7
529	G-CSF administration in a small-for-size liver model. 2009 , 22, 167-77	17
528	Innate immune dysfunction in acute and chronic liver disease. 2009 , 121, 732-44	33
527	Probiotics and immunity. 2009, 44, 26-46	329
526	Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. 2009 , 29, 1273-81	99
525	Effect of hyponatraemia on outcomes following orthotopic liver transplantation. 2009 , 29, 1071-7	58
524	Lack of effect of norfloxacin on hyperdynamic circulation in bile duct-ligated rats despite reduction of endothelial nitric oxide synthase function: result of unchanged vascular Rho-kinase?. 2009 , 29, 933-41	8
523	Identification of bacterial DNA in neutrocytic and non-neutrocytic cirrhotic ascites by means of a multiplex polymerase chain reaction. 2009 , 29, 1206-14	43
522	Toll-like receptors as targets in chronic liver diseases. 2009 , 58, 704-20	247
521	Clinical characteristics and outcomes of pneumococcal bacteremia in adult patients with liver cirrhosis. 2009 , 63, 160-4	15
520	Impact of liver cirrhosis on mortality in patients with community-acquired bacteremia. 2009, 64, 124-30	29
519	Low serum concentration of apolipoprotein A-I is an indicator of poor prognosis in cirrhotic patients with severe sepsis. <i>Journal of Hepatology</i> , 2009 , 50, 906-15	45
518	Alcoholic hepatitis. 2009 , 360, 2758-69	644
517	Ascites: diagnosis and management. 2009 , 93, 801-17, vii	61
516	Ascites: pathogenesis and therapeutic principles. 2009 , 44, 902-11	35
515	Renal failure in cirrhosis. 2009 , 361, 1279-90	571
514	Hepatic encephalopathy. 2009, 27, 401-14	34
513	25 Einsatz von Probiotika und Synbiotika bei Lebererkrankungen. 2009 ,	

512	The impact of nutrition on cirrhotic patients awaiting liver transplantation. 2010, 13, 554-61		26
511	Is detection of bacterial DNA in ascitic fluid of clinical relevance?. 2010 , 22, 1487-94		26
510	Cardiorenal Syndrome 🖟 New Entity?. 2010 , 102-111		5
509	Role of Infections in Hepatorenal Syndrome. 2010 , 130-141		
508	Intestinal flora imbalance results in altered bacterial translocation and liver function in rats with experimental cirrhosis. 2010 , 22, 1481-6		41
507	Hepatorenal syndrome. 2010 , 103, 654-61		15
506	Proteomic evidence of bacterial peptide translocation in afebrile patients with cirrhosis and ascites. 2010 , 88, 487-95		8
505	Spontan bakterielle Peritonitis bei Leberzirrhose. 2010 , 47, 571-575		
504	The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. 2010 , 4, 659-72		185
503	Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. 2010 , 55, 1465-71		65
502	Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. <i>Hepatology</i> , 2010 , 51, 1327-33	11.2	98
501	Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. 2010 , 10, 72		31
500	Attenuation of toll-like receptor 2-mediated innate immune response in patients with alcoholic chronic liver disease. 2010 , 30, 1003-11		18
499	Alcohol takes the toll on immune function. 2010 , 30, 934-6		3
498	Presence of anti-microbial antibodies in liver cirrhosisa tell-tale sign of compromised immunity?. <i>PLoS ONE</i> , 2010 , 5, e12957	3.7	38
497	Spontaneous Bacterial Peritonitis i Prophylaxis and Treatment. 2010, 65-82		
496	[Ascites, hepatorenal syndrome and spontaneous bacterial peritonitis in patients with portal hypertension]. 2010 , 56, 168-85		1
495	Pre- and Probiotics in Liver Health and Function. 2010 , 97-116		

(2011-2010)

494	Use of plasma procalcitonin levels as an adjunct to clinical microbiology. 2010 , 48, 2325-9	102
493	Splanchnic sympathectomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis. 2010 , 59, 1127-34	45
492	SEdrome hepatorenal: patogEesis y tratamiento. 2010 , 21, 613-622	
491	Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed?. 2010 , 105, 323-7	79
490	Toll-like receptor 4 and hepatic fibrogenesis. 2010 , 30, 232-44	107
489	Pathophysiologie der portalen Hypertension als Voraussetzung innovativer Therapien. 2010 , 60, 717-718	
488	Neutrophil migration during liver injury is under nucleotide-binding oligomerization domain 1 control. 2010 , 138, 1546-56, 1556.e1-5	30
487	Genetic diversity and virulence profiles of Escherichia coli isolates causing spontaneous bacterial peritonitis and bacteremia in patients with cirrhosis. 2010 , 48, 2709-14	57
486	Bacterial translocation in a rat model of large volume hepatic radiofrequency ablation. 2010 , 161, 250-8	9
485	Renal and circulatory dysfunction in cirrhosis: current management and future perspectives.	83
	Journal of Hepatology, 2010 , 53, 1135-45	
484	[Current problems in the prevention and treatment of infections in patients with cirrhosis]. 2010, 33, 729-40	3
484	[Current problems in the prevention and treatment of infections in patients with cirrhosis]. 2010 ,	
	[Current problems in the prevention and treatment of infections in patients with cirrhosis]. 2010, 33, 729-40	3
483	[Current problems in the prevention and treatment of infections in patients with cirrhosis]. 2010, 33, 729-40 [Chronic liver failure: a clinical entity in need of researchers]. 2010, 33, 619-20 Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic	3
483	[Current problems in the prevention and treatment of infections in patients with cirrhosis]. 2010, 33, 729-40 [Chronic liver failure: a clinical entity in need of researchers]. 2010, 33, 619-20 Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation. 2011, 15, 233	3 0 33
483 482 481	[Current problems in the prevention and treatment of infections in patients with cirrhosis]. 2010, 33, 729-40 [Chronic liver failure: a clinical entity in need of researchers]. 2010, 33, 619-20 Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation. 2011, 15, 233 Immune dysfunction and infections in patients with cirrhosis. 2011, 9, 727-38	3 0 33 233
483 482 481 480	[Current problems in the prevention and treatment of infections in patients with cirrhosis]. 2010, 33, 729-40 [Chronic liver failure: a clinical entity in need of researchers]. 2010, 33, 619-20 Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation. 2011, 15, 233 Immune dysfunction and infections in patients with cirrhosis. 2011, 9, 727-38 Gut microbiota and probiotics in chronic liver diseases. 2011, 43, 431-8	3 0 33 233 115

476	Phenotypic polymorphism of haptoglobin: a novel risk factor for the development of infection in liver cirrhosis. 2011 , 72, 348-54	9
475	[Beta-blockers in portal hypertension: Unexpected limitations!]. 2011, 40, 227-9	
474	Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. <i>Journal of Hepatology</i> , 2011 , 55, 1010-6	75
473	Gastrointestinal Structure and Function. 2011 , 1207-1220	1
472	Pathophysiological basis of albumin use in cirrhosis. 2011 , 10, S6-S14	24
471	Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis. <i>PLoS ONE</i> , 2011 , 6, e23037	92
470	Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt. 2011 , 23, 1218-25	55
469	The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection. 2011 , 164, 346-56	28
468	Circulating nitric oxide products do not solely reflect nitric oxide release in cirrhosis and portal hypertension. 2011 , 31, 1381-7	5
467	Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis. 2011 , 31, 1406-15	34
466	Procalcitonin as a biomarker for bacterial infections in patients with liver cirrhosis in the emergency department. 2011 , 18, 121-6	32
465	Status of bacterial colonization, Toll-like receptor expression and nuclear factor-kappa B activation in normal and diseased human livers. 2011 , 138, 41-9	35
464	Mechanical intestinal cleansing and antibiotic prophylaxis for preventing bacterial translocation during the Pringle maneuver in rabbits. 2011 , 41, 824-8	6
463	Pringle maneuver deteriorates gut barrier dysfunction induced by extended-liver radiofrequency ablation. 2011 , 56, 1548-56	10
462	Risk factors for mortality in cirrhotic patients with sepsis. 2011 , 5, 800-7	10
461	Management of refractory ascites and hepatorenal syndrome. 2011 , 13, 17-25	7
460	The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS). 2011 , 11, 107	15
459	Enteric dysbiosis associated with a mouse model of alcoholic liver disease. <i>Hepatology</i> , 2011 , 53, 96-105 _{11.2}	494

458	Liver cirrhosis. 2011 , 25, 281-90	141
457	Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. 2011 , 22, 699-711	138
456	Predictive Value of the Model of End-Stage Liver Disease in Cirrhotic Patients with and without Spontaneous Bacterial Peritonitis. 2012 , 2012, 539059	13
455	Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence. 2012 , 18, 700-8	47
454	Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. 2012 , 303, G675-85	331
453	Cytokines in liver, biliary, and pancreatic disease. 2012 , 166-180.e3	2
452	Infectious complications of acute and chronic liver disease. 2012 , 33, 80-95	76
451	Predictive value of acute kidney injury in medical intensive care patients with sepsis originating from different infection sites. 2012 , 344, 83-9	11
450	Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease. World Journal of Hepatology, 2012 , 4, 110-8	79
449	Protocolo diagnEtico del paciente con cirrosis y fiebre. 2012 , 11, 667-670	
448	Management of bacterial infections in cirrhosis. <i>Journal of Hepatology</i> , 2012 , 56 Suppl 1, S1-12	244
447	[Primary antibiotic prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients is a matter of target!]. 2012 , 41, 1168-70	1
446	Gut bacterial translocation contributes to microinflammation in experimental uremia. 2012 , 57, 2856-62	69
445	Changes of gut bacteria and immune parameters in liver transplant recipients. 2012 , 11, 40-50	78
444	Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. 2012 , 17, 733-8	126
443	A mucormycosis case in a cirrhotic patient successfully treated with posaconazole and review of published literature. 2012 , 174, 499-504	10
442	Intra-abdominal and pelvic emergencies. 2012 , 96, 1171-91	8
441	Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. 2012 , 141, 55-62	291

440	Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections. 2012 , 32, 603-11		67
439	Mycobacterial peritonitis: difference between non-tuberculous mycobacteria and Mycobacterium tuberculosis. 2012 , 18, 246-52		11
438	Bacterial resistance in cirrhotic patients: an emerging reality. Journal of Hepatology, 2012, 56, 756-7	13.4	11
437	Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. Journal of Hepatology, 2012 , 56, 1283-92	13.4	219
436	Gut microbiome and intestinal barrier failurethe "Achilles heel" in hepatology?. <i>Journal of Hepatology</i> , 2012 , 56, 1221-3	13.4	34
435	Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. <i>Journal of Hepatology</i> , 2012 , 57, 803-12	13.4	152
434	[Physiopathological bases for the use of human albumin in liver cirrhosis]. 2012, 35, 42-9		1
433	Selective activation of Toll-like receptor 7 in activated hepatic stellate cells may modulate their profibrogenic phenotype. 2012 , 447, 25-34		19
432	Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. 2012 , 44, 239-44		15
431	Hepatorenal Syndrome. 2012 , 1, e62-e68		О
430	[Spontaneous bacterial peritonitis]. 2012 , 107, 548-52		1
	[Spontaneous bacterial peritonitis]. 2012 , 107, 548-52 Beta-adrenergic receptor 1 selective antagonism inhibits norepinephrine-mediated TNF-alpha downregulation in experimental liver cirrhosis. <i>PLoS ONE</i> , 2012 , 7, e43371	3.7	9
430	Beta-adrenergic receptor 1 selective antagonism inhibits norepinephrine-mediated TNF-alpha	3.7	
430	Beta-adrenergic receptor 1 selective antagonism inhibits norepinephrine-mediated TNF-alpha downregulation in experimental liver cirrhosis. <i>PLoS ONE</i> , 2012 , 7, e43371 HGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation		9
43 ⁰ 429 428	Beta-adrenergic receptor 1 selective antagonism inhibits norepinephrine-mediated TNF-alpha downregulation in experimental liver cirrhosis. <i>PLoS ONE</i> , 2012 , 7, e43371 HGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation through TLR4/NF-kB pathway. <i>PLoS ONE</i> , 2012 , 7, e43408		9 35
430 429 428 427	Beta-adrenergic receptor 1 selective antagonism inhibits norepinephrine-mediated TNF-alpha downregulation in experimental liver cirrhosis. <i>PLoS ONE</i> , 2012 , 7, e43371 HGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation through TLR4/NF-kB pathway. <i>PLoS ONE</i> , 2012 , 7, e43408 Acute kidney injury in critically ill cirrhotic patients: a review. 2012 , 11, 301-310 The effect of intestinal permeability and endotoxemia on the prognosis of acute pancreatitis. <i>Gut</i>	3.7	9 35 7
430 429 428 427 426	Beta-adrenergic receptor 1 selective antagonism inhibits norepinephrine-mediated TNF-alpha downregulation in experimental liver cirrhosis. <i>PLoS ONE</i> , 2012 , 7, e43371 HGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation through TLR4/NF-kB pathway. <i>PLoS ONE</i> , 2012 , 7, e43408 Acute kidney injury in critically ill cirrhotic patients: a review. 2012 , 11, 301-310 The effect of intestinal permeability and endotoxemia on the prognosis of acute pancreatitis. <i>Gut and Liver</i> , 2012 , 6, 505-11	3.7	9 35 7 32

422	Spontaneous bacterial peritonitis: recent guidelines and beyond. 2012 , 61, 297-310	246
421	Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. 2012 , 590, 447-58	270
420	Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals. 2012 , 65, 7-13	54
419	Susceptibility to spontaneous bacterial peritonitisare genetics the future?. 2012 , 32, 177-8	1
418	Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. 2012 , 21, 504-16	790
417	Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis. 2012 , 59, 874-85	47
416	Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. 2012 , 36, 764-85	568
415	Altered intestinal tight junctions Axpression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. 2012 , 42, 439-46	100
414	Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. 2012 , 42, 760-7	38
413	The new epidemiology of nosocomial bacterial infections in cirrhosis: therapeutical implications. 2013 , 7, 72-9	16
412	Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective Eblockers. 2013, 30, 659-70	21
411	Effects of inferior mesenteric vein flow in patients with cirrhosis. 2013 , 11, 1648-54	7
410	Infells bacterianas no doente com cirrose heplica. 2013 , 20, 58-65	2
409	Functional relevance of the cannabinoid receptor 2 - heme oxygenase pathway: a novel target for the attenuation of portal hypertension. 2013 , 93, 543-51	12
408	The microbiome and cancer. 2013 , 13, 800-12	936
407	Non-hemorrhagic acute complications associated with cirrhosis and portal hypertension. 2013 , 27, 665-78	6
406	Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. 2013 , 28, 450-5	143
405	So depression is an inflammatory disease, but where does the inflammation come from?. 2013 , 11, 200	690

404	Life-threatening infections in medically immunocompromised patients. 2013 , 29, 807-26	5
403	A French national survey on the use of antibiotic prophylaxis in cirrhotic patients. 2013 , 33, 389-97	10
402	Acute renal failure in cirrhotic patients with severe sepsis: value of urinary interleukin-18. 2013 , 28, 135-41	14
401	Reply to: "Uncovering the molecular events associated with increased intestinal permeability in liver cirrhosis: The pivotal role of enterocyte tight junctions and future perspectives". <i>Journal of Hepatology</i> , 2013 , 59, 1146-7	1
400	Intestinal GATA4 deficiency induces proximal fibroblast growth factor 15 expression and represses hepatic gluconeogenesis. <i>Journal of Hepatology</i> , 2013 , 59, 1147-9	1
399	Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. 2013 , 28, 235-42	94
398	Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. 2013 , 33, 31-9	155
397	Regulation of wound healing and organ fibrosis by toll-like receptors. 2013 , 1832, 1005-17	99
396	In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. 2013 , 127, 344-54	134
395	Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. 2013 , 33, 1457-69	73
394	High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013 , 59, 457-66	27
393	Hepatorenal syndrome in the intensive care unit. 2013 , 28, 79-92	8
392	No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion. 2013 , 33, 1309-15	17
391	Frequency and severity of cirrhotic cardiomyopathy and its possible relationship with bacterial endotoxemia. 2013 , 58, 3029-36	28
390	Relationship between urinary fractional excretion of sodium and life prognosis in liver cirrhosis patients. 2013 , 43, 1156-62	8
389	Postoperative peritonitis without an underlying digestive fistula after complete cytoreductive surgery plus HIPEC. 2013 , 19, 271-7	4
388	Fatal Nocardia cyriacigeorgica spontaneous bacterial peritonitis. 2013 , 1, 32-3	
387	Dysregulation of toll-like receptor (TLR) 2 expression on monocytes and upregulation of the frequency of T cells expressing TLR2 in patients with chronic hepatitis C virus infection. 2013 , 121, 437-46	4

386	Hospital mortality of cirrhosis: better, but still room for improvement!. 2013 , 33, 809-10		1
385	Citrobacter peritoneal dialysis peritonitis: rare occurrence with poor outcomes. 2013 , 10, 1092-8		15
384	Diagnosis and management of bacterial infections in decompensated cirrhosis. World Journal of Hepatology, 2013 , 5, 16-25	-4	36
383	Acute-on-chronic liver failure: a review. 2014 , 10, 295-303		29
382	Probiotics (VSL#3) prevent endothelial dysfunction in rats with portal hypertension: role of the angiotensin system. <i>PLoS ONE</i> , 2014 , 9, e97458	··7	36
381	Is there a role for probiotics in liver disease?. 2014 , 2014, 874768		15
380	Non-alcoholic steatohepatitis and hepatocellular carcinoma: implications for lycopene intervention. 2013 , 6, 124-62		36
379	Spontaneous Bacterial Peritonitis and Bacteremia in Patients with Liver Cirrhosis. 2014 , 03,		1
378	New determinants of prognosis in bacterial infections in cirrhosis. 2014 , 20, 7252-9		20
377	The impact of bacterial infections on survival of patients with decompensated cirrhosis. 2014 , 13, 7-19		16
376	Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 9422-58	ó.3	59
375	Non-typhoidal salmonella: an unusual cause of spontaneous bacterial peritonitis in decompensated cirrhosis. 2014 , 2, 242-4		3
374	Microbiome composition by pyrosequencing in mesenteric lymph nodes of rats with CCl4-induced cirrhosis. 2014 , 6, 263-71		15
373	Functional gene arrays-based analysis of fecal microbiomes in patients with liver cirrhosis. 2014 , 15, 753		24
372	Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. 2014 , 5, 177		91
371	Ascites and spontaneous bacterial peritonitis: recommendations from two United States centers. 2014 , 20, 279-87		13
370	The potential of lipopolysaccharide-binding protein to predict the severity and prognosis of cirrhotic patients with severe sepsis. 2014 , 77, 57-8		
369	Lipopolysaccharide binding protein in cirrhotic patients with severe sepsis. 2014 , 77, 68-74		11

368	Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2014 , 60, 1055-62	57
367	The emerging roles of microvesicles in liver diseases. 2014 , 11, 350-61	130
366	Laboratory diagnostics of spontaneous bacterial peritonitis. 2014 , 430, 164-70	16
365	Protective effect of Bifidobacterium pseudocatenulatum CECT7765 against induced bacterial antigen translocation in experimental cirrhosis. 2014 , 34, 850-8	34
364	Role of toll-like receptors in liver transplantation. 2014 , 20, 270-80	19
363	Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. 2014 , 34, 1504-12	52
362	Variceal Hemorrhage. 2014 ,	2
361	[Hepatorenal syndrome]. 2014 , 10, 61-8	3
360	Cardiac and proinflammatory markers predict prognosis in cirrhosis. 2014 , 34, e19-30	54
359	Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. 2014 , 40, 695-704	74
358	Reply to: "bacterial translocation in liver cirrhosis: site and role in fibrogenesis". <i>Journal of Hepatology</i> , 2014 , 61, 710-1	4
357	Alterations of the human gut microbiome in liver cirrhosis. 2014 , 513, 59-64	1155
356	Cirrhotic cardiomyopathy: review of pathophysiology and treatment. 2014 , 8, 308-15	49
355	NASH and the Cross-Talk Between the Gut and Liver. 2014 , 2, 211-217	1
354	Large intestine permeability is increased in patients with compensated liver cirrhosis. 2014 , 306, G147-53	28
353	Connecting the dots: could microbial translocation explain commonly reported symptoms in HIV disease?. 2014 , 25, 483-95	8
352	Bacterial translocation in liver cirrhosis: site and role in fibrogenesis. <i>Journal of Hepatology</i> , 2014 , 61, 709-10	3
351	[Spontaneous bacteremia due to Campylobacter coli in a cirrhotic patient]. 2014 , 32, 470-1	1

Inflammation and portal hypertension - the undiscovered country. Journal of Hepatology, 2014, 61, 155-63,4 350 [Group C Streptococcus meningitis: a case report]. 2014, 32, 333-4 349 [Bacteraemia due to Streptococcus equi spp. zooepidemicus in a liver transplant recipient]. 2014, 348 \circ 32, 332-3 Interleukin 10 promoter haplotype is associated with alcoholic liver cirrhosis in Taiwanese patients. 9 2014, 30, 291-8 Metabolism of Human Diseases. 2014, 346 4 Oxidative & nitrosative stress in depression: why so much stress?. 2014, 45, 46-62 345 263 Gut microbiota-related complications in cirrhosis. 2014, 20, 15624-31 344 35 Proton pump inhibitor use is associated with spontaneous bacterial peritonitis in patients with liver 17 343 cirrhosis. 2014, 53, 1037-42 Diagnostic utility of interferon gamma-induced protein 10 kDa in spontaneous bacterial peritonitis: 342 17 single-center study. 2015, 27, 1087-93 Salivary microbiota-immune profiling in cirrhosis: could this be the noninvasive strategy that will 8 11.2 341 revolutionize prognostication in hepatology?. Hepatology, 2015, 62, 1001-3 Interleukin-1 receptor antagonist correlates with hepatic venous pressure gradient and predicts 340 1 occurrence of overall complications and bacterial infections in patients with cirrhosis. 2015, 45, 294-304 Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. 2015, 30, 1429-37 339 93 Attenuated portal hypertension in germ-free mice: Function of bacterial flora on the development 338 11.2 33 of mesenteric lymphatic and blood vessels. Hepatology, 2015, 61, 1685-95 Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with 337 45 diarrhea-predominant irritable bowel syndrome. 2015, 27, 1747-54 Impact of Gastrointestinal Bacillus anthracis Infection on Hepatic B Cells. 2015, 7, 3805-17 336 Hepatorenal syndrome: Update on diagnosis and treatment. **2015**, 4, 511-20 335 Protective Effect of the Total Saponins from Rosa laevigata Michx Fruit against Carbon 334 25 Tetrachloride-Induced Liver Fibrosis in Rats. 2015, 7, 4829-50 Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis. World Journal of 333 3.4 55 Hepatology, **2015**, 7, 1974-81

332	Mean platelet volume as a novel predictor of systemic inflammatory response in cirrhotic patients with culture-negative neutrocytic ascites. <i>World Journal of Hepatology</i> , 2015 , 7, 1001-6	3.4	3
331	Bacterial Infections in Patients with Cirrhosis. 2015 , 229-241		
330	Effects of Lycium barbarum on bacterial translocation in thioacetamide-induced liver injury in rats. 2015 , 13, 154-163		4
329	The gutBrain axis: The role of melatonin in linking psychiatric, inflammatory and neurodegenerative conditions. 2015 , 2, 31-37		25
328	Ascites. 2015 , 151-163		
327	Immunologic, hemodynamic, and adrenal incompetence in cirrhosis: impact on renal dysfunction. 2015 , 9, 17-27		6
326	The human microbiome: opportunities and challenges for clinical care. 2015 , 45, 889-98		6
325	Portal Hypertension Reversibility with Treatment of Underlying Liver Disease. 2015 , 14, 219-224		1
324	The dormant blood microbiome in chronic, inflammatory diseases. 2015 , 39, 567-91		236
323	Appropriate Use of Beta Blockers in Cirrhosis. 2015 , 14, 243-249		
322			
	Infection as a Trigger for Portal Hypertension. 2015 , 33, 570-6		17
321	Infection as a Trigger for Portal Hypertension. 2015 , 33, 570-6 Cirrhotic Multiorgan Syndrome. 2015 , 60, 3209-25		17 28
			,
321	Cirrhotic Multiorgan Syndrome. 2015 , 60, 3209-25		28
321	Cirrhotic Multiorgan Syndrome. 2015 , 60, 3209-25 Implication of gut microbiota in nonalcoholic fatty liver disease. 2015 , 11, e1004559		28
321 320 319	Cirrhotic Multiorgan Syndrome. 2015, 60, 3209-25 Implication of gut microbiota in nonalcoholic fatty liver disease. 2015, 11, e1004559 Pretransplantation Evaluation. 2015, 419-440 The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with		28 91
321 320 319 318	Cirrhotic Multiorgan Syndrome. 2015, 60, 3209-25 Implication of gut microbiota in nonalcoholic fatty liver disease. 2015, 11, e1004559 Pretransplantation Evaluation. 2015, 419-440 The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial. 2015, 16, 83		28 91

314	Hepatorenal Disorders. 2015 , 148, 550-558	13
313	Review article: spontaneous bacterial peritonitisbacteriology, diagnosis, treatment, risk factors and prevention. 2015 , 41, 1116-31	94
312	B-cell-associated immune profiles in patients with decompensated cirrhosis. 2015 , 50, 884-91	3
311	Artesunate alleviates hepatic fibrosis induced by multiple pathogenic factors and inflammation through the inhibition of LPS/TLR4/NF- B signaling pathway in rats. 2015 , 765, 234-41	48
310	Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension. 2015 , 35, 1393-402	9
309	[Spontaneous bacterial peritonitis in patients with cirrhosis]. 2015 , 44, 1235-42	
308	Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. 2015 , 13, 753-9.e1-2	81
307	Bacterial translocation and endotoxemia after pringle maneuver in cirrhotic rats. 2015 , 60, 414-9	6
306	Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure. 2015 , 35, 724-34	67
305	Infective endocarditis due to Enterobacter cloacae resistant to third- and fourth-generation cephalosporins. 2015 , 48, 226-8	10
304	The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. 2015 , 35, 362-9	68
303	Renal insufficiency in the patient with chronic liver disease. <i>Clinics in Liver Disease</i> , 2015 , 19, 45-56 4.6	12
302	Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis. 2015 , 35, 37-45	33
301	Chronic Kidney Disease and Liver Disease. 2015 , 544-559	O
300	PREVALENCE OF BACTERIAL RESISTANCE IN HOSPITALIZED CIRRHOTIC PATIENTS IN SOUTHERN BRAZIL: A NEW CHALLENGE. 2016 , 58, 36	6
299	Infections in severe alcoholic hepatitis. <i>Annals of Gastroenterology</i> , 2017 , 30, 152-160 2.2	15
298	Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis. 2016 , 22, 9257-9278	41
297	Translocation of Klebsiella from Enteral Diets: Study through Mouse Model System and Molecular Technique. 2016 , 07,	

296	Ascitic Fluid Calprotectin and Serum Procalcitonin as Accurate Diagnostic Markers for Spontaneous Bacterial Peritonitis. <i>Gut and Liver</i> , 2016 , 10, 624-31	4.8	29
295	Bacterial infections in cirrhosis: A critical review and practical guidance. <i>World Journal of Hepatology</i> , 2016 , 8, 307-21	3.4	108
294	Extensively drug-resistant bacteria are an independent predictive factor of mortality in 130 patients with spontaneous bacterial peritonitis or spontaneous bacteremia. 2016 , 22, 4049-56		34
293	Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. 2017 , 109, 17-25		12
292	Is intestinal oxidative stress involved in patients with compensated liver cirrhosis?. 2016 , 15, 402-9		4
291	Fulminant ulcerative colitis complicated by treatment-refractory bacteremia. 2016, 29, 407-408		1
290	The pathophysiology of thrombocytopenia in chronic liver disease. 2016 , 8, 39-50		71
289	Gut Microbiome and Gastrointestinal Cancer: Les liaisons Dangereuses. 2016 , 50 Suppl 2, Proceedings from t, S191-S196		22
288	Microbiome and bacterial translocation in cirrhosis. 2016 , 39, 687-696		1
287	Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF- B /HIF-1\(\overline{\Pha}\) athway. 2016 , 378, 131-41		22
286	Predisposing Factors in Acute-on-Chronic Liver Failure. 2016 , 36, 167-73		19
285	Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis. 2016 , 44, 926-935		62
284	Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways. 2016 , 21, 184-98		112
283	High-Output Heart Failure: A 15-Year Experience. 2016 , 68, 473-482		125
282	The impact of proton pump inhibitor therapy on patients with liver disease. 2016 , 44, 1213-1223		22
281	Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. 2016 , 6, 340!	55	102
280	Detection of molecular bacterascites in decompensated cirrhosis defines a risk with decreased survival. 2016 , 28, 1285-92		7
279	Patients with end-stage renal disease were at an increased risk of hospitalization for acute diverticulitis. 2016 , 95, e4881		5

278	Changes of Intestinal Functions in Liver Cirrhosis. 2016 , 1, 24-40		25
277	Age-dependent development of liver fibrosis in Glmp (gt/gt) mice. 2016 , 9, 5		3
276	The intestinal microbiome and surgical disease. 2016 , 53, 257-93		16
275	Changes in gut toll-like receptor-4 and nod-like receptor family pyrin domain containing-3 innate pathways in liver cirrhosis rats with bacterial translocation. 2016 , 40, 575-583		O
274	Antibiotic prophylaxis in cirrhosis: Good and bad. <i>Hepatology</i> , 2016 , 63, 2019-31	11.2	108
273	Bacterial Translocation and Sample Contamination in Postmortem Microbiological Analyses. 2016 , 61, 367-374		17
272	Bifidobacterium pseudocatenulatum CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis. 2016 , 55, 197-206		14
271	Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. 2016 , 11, 3-10		6
270	Novel prevention strategies for bacterial infections in cirrhosis. 2016 , 17, 689-701		13
269	Microbiome and bacterial translocation in cirrhosis. 2016 , 39, 687-696		10
268	Nucleotide-Binding Oligomerization Domain-Containing Protein 2 Variants in Patients with Spontaneous Bacterial Peritonitis. 2016 , 61, 1545-52		10
267	Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: A meta-analysis. 2016 , 48, 353-9		39
266	Monomicrobial Aeromonas and Vibrio bacteremia in cirrhotic adults in southern Taiwan: Similarities and differences. 2016 , 49, 509-15		9
265	Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. 2016 , 37, 1684-91		112
264	Brain-gut-microbiota axis: challenges for translation in psychiatry. 2016 , 26, 366-72		120
263	Nonalcoholic Fatty Liver Disease and the Gut Microbiome. <i>Clinics in Liver Disease</i> , 2016 , 20, 263-75	4.6	58
262	Bifidobacterium pseudocatenulatum CECT7765 induces an M2 anti-inflammatory transition in macrophages from patients with cirrhosis. <i>Journal of Hepatology</i> , 2016 , 64, 135-45	13.4	16
261	Clinical science workshop: targeting the gut-liver-brain axis. 2016 , 31, 1327-1337		16

260	The potential risks of probiotics among HIV-infected persons: Bacteraemia due to Lactobacillus acidophilus and review of the literature. 2016 , 27, 1223-1230		38
259	Bacterial translocation aggravates CCl-induced liver cirrhosis by regulating CD4 T cells in rats. 2017 , 7, 40516		9
258	Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study. 2017 , 40, 153-167		13
257	RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis. <i>Journal of Hepatology</i> , 2017 , 66, 1205-1213	3.4	30
256	The impact of infections on delisting patients from the liver transplantation waiting list. 2017 , 30, 807-816	;	7
255	Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention. 2017 , 35, 402-410		19
254	FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients. <i>Hepatology</i> , 2017 , 66, 1286-1295	1.2	17
253	NADPH oxidase 4 modulates hepatic responses to lipopolysaccharide mediated by Toll-like receptor-4. 2017 , 7, 14346		18
252	Mosapride Stabilizes Intestinal Microbiota to Reduce Bacterial Translocation and Endotoxemia in CCl-Induced Cirrhotic Rats. 2017 , 62, 2801-2811		4
251	Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. 2017 , 46, 845-855		53
250	Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis. 2017 , 46, 920-937		19
249	Bifidobacterium pseudocatenulatum LI09 and Bifidobacterium catenulatum LI10 attenuate D-galactosamine-induced liver injury by modifying the gut microbiota. 2017 , 7, 8770		45
248	Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis. 2017 , 62, 2277-2292		39
247	Is periodontitis a risk factor for infections in cirrhotic patients?. 2017 , 106, 19-22		3
246	The gut microbiome and liver cancer: mechanisms and clinical translation. 2017 , 14, 527-539		252
245	Ascites, refractory ascites and hyponatremia in cirrhosis. 2017 , 5, 104-112		31
244	Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis. 2017 , 32, 1064-1070		23
243	Gut microbiome and liver disease. 2017 , 179, 49-59		58

(2018-2017)

242	Gut Microbiota, Bacterial Translocation, and Interactions with Diet: Pathophysiological Links between Major Depressive Disorder and Non-Communicable Medical Comorbidities. 2017 , 86, 31-46		125
241	PCR-detected fungal infection is associated with fatal outcomes in cirrhotic patients with spontaneous peritonitis. 2017 , 4, 42-46		1
240	Systematic Review and Meta-Analysis: Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Liver Disease. 2017 , 37, 388-400		34
239	Bacterial translocation markers in liver cirrhosis. <i>Annals of Gastroenterology</i> , 2017 , 30, 486-497	2.2	42
238	[Spontaneous bacterial peritonitis]. 2017 , 158, 50-57		2
237	Complications of Cirrhosis: Introduction. 2017 , 427-433		1
236	Detection of bacterial DNA by in situ hybridization in patients with decompensated liver cirrhosis. 2017 , 17, 106		5
235	Probiotics for the Treatment of Liver Disease. 2017 , 373-381		3
234	Bacterial infections in patients with liver cirrhosis: clinical characteristics and the role of C-reactive protein. <i>Annals of Gastroenterology</i> , 2018 , 31, 77-83	2.2	3
233	Homocysteine: a new diagnostic marker in spontaneous bacterial peritonitis. 2018 , 30, 779-785		14
232	Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management. 2018 , 63, 1706-1725		11
232		13.4	
	for Future Management. 2018 , 63, 1706-1725 EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.	13.4	11
231	for Future Management. 2018, 63, 1706-1725 EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology, 2018, 69, 406-460 Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in	13.4	930
231	for Future Management. 2018, 63, 1706-1725 EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology, 2018, 69, 406-460 Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients. 2018, 32, 1095-1105 The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of	13.4	11 930 20
231 230 229	For Future Management. 2018, 63, 1706-1725 EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology, 2018, 69, 406-460 Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients. 2018, 32, 1095-1105 The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?. 2018, 67, 878-880	13.4	11 930 20
231 230 229 228	EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology, 2018, 69, 406-460 Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients. 2018, 32, 1095-1105 The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?. 2018, 67, 878-880 Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. 2018, 12, 24-33 Novelties in the pathophysiology and management of portal hypertension: new treatments on the	13.4	11 930 20 1

224	Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis. 2018 , 38, 295-302	10
223	Functional polymorphisms of innate immunity receptors are not risk factors for the non-SBP type bacterial infections in cirrhosis. 2018 , 38, 1242-1252	6
222	Effect of Proton Pump Inhibitors on Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. 2018 , 17, 933-939	9
221	Nutraceutical-Based Pharmacological Intervention in the Management of Liver Diseases. 2018 , 375-394	
220	Regulatory T Cells Restrict Permeability to Bacterial Antigen Translocation and Preserve Short-Chain Fatty Acids in Experimental Cirrhosis. 2018 , 2, 1610-1623	11
219	Kidney Injury and Electrolyte Abnormalities in Liver Failure. 2018 , 39, 556-565	5
218	Danger-Associated Molecular Patterns (DAMPs): the Derivatives and Triggers of Inflammation. 2018 , 18, 63	79
217	Acute Kidney Injury and Liver Disease: Incidence, Pathophysiology, Prevention/Treatment, and Outcomes. 2018 , 113-131	
216	Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. 2018 , 12, 641-656	51
215	Large-scale screening of circulating microRNAs in individuals with HIV-1 mono-infections reveals specific liver damage signatures. 2018 , 155, 106-114	3
214	Treatment with non-selective beta-blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis. 2018 , 38, 2219-2227	8
213	Ascitic fluid regulates the local innate immune response of patients with cirrhosis. 2018, 104, 833-841	5
212	Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. 2018 , 8, 8210	38
211	A Flowthrough Assay for Rapid Bedside Stratification of Bloodstream Bacterial Infection in Critically Ill Patients: a Pilot Study. 2018 , 56,	3
21 0	Microbiota, Epithelium, Inflammation, and TGF-Lagrangian An Intricate Interaction in Oncogenesis. Frontiers in Microbiology, 2018, 9, 1353	16
209	Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure. 2018 , 34, 270-275	20
208	Microbiology and antibiotic susceptibility patterns in spontaneous bacterial peritonitis: A study of two Dutch cohorts at a 10-year interval. 2018 , 6, 614-621	10
207	Hepatic Cirrhosis. 2018 , 107-126	2

(2019-2019)

206	Perioperative enteral supplementation with glutamine, fiber, and oligosaccharide reduces early postoperative surgical stress following esophagectomy for esophageal cancer. 2019 , 16, 63-70		6
205	Improved hemodynamic and liver function in portal hypertensive cirrhotic rats after administration of B. pseudocatenulatum CECT 7765. 2019 , 58, 1647-1658		7
204	A multicenter study on clinical characteristics of Acinetobacter bacteremia in patients with liver cirrhosis. 2019 , 52, 956-965		3
203	Prevalence and predictors for spontaneous bacterial peritonitis in cirrhotic patients with ascites admitted at medical block in Korle-Bu Teaching Hospital, Ghana. 2019 , 33, 35		8
202	Pretreatment With Preserves Against D-Galactosamine-Induced Liver Injury in a Rat Model. <i>Frontiers in Microbiology</i> , 2019 , 10, 1751	5.7	9
201	[Long-term drug treatments to improve prognosis of patients with liver cirrhosis and to prevent complications due to portal hypertension]. 2019 , 57, 983-996		O
200	Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. 2019 , 33, 11595-11605		32
199	Dysbiosis of the gut microbiome is associated with CKD5 and correlated with clinical indices of the disease: a case-controlled study. 2019 , 17, 228		18
198	FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. <i>Journal of Hepatology</i> , 2019 , 71, 1126-1140	13.4	77
197	The gut microbiome in psychiatry: A primer for clinicians. 2019 , 36, 1004-1025		17
196	Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. 2019 , 7, 267		63
195	Portal Hypertension: Pathogenesis and Diagnosis. <i>Clinics in Liver Disease</i> , 2019 , 23, 573-587	4.6	31
194	Evaluation of Intestinal Permeability and Liver Bacterial Translocation in Two Modern Broilers and Their Jungle Fowl Ancestor. 2019 , 10, 480		4
193	Microbial Profiles of Cirrhosis in the Human Small Intestine. 2019 , 21, 50		1
192	Exopolysaccharides from TCP016 Attenuate LPS- and d-GalN-Induced Liver Injury by Modulating the Gut Microbiota. 2019 , 67, 11627-11637		13
191	Oral Phosphatidylcholine Improves Intestinal Barrier Function in Drug-Induced Liver Injury in Rats. 2019 , 2019, 8723460		9
190	Cholestasis-associated reproductive toxicity in male and female rats: The fundamental role of mitochondrial impairment and oxidative stress. 2019 , 316, 60-72		29
189	Plasma diamine oxidase level predicts 6-month readmission for patients with hepatitis B virus-related decompensated cirrhosis. 2019 , 16, 115		1

188	Combination of vial culture and broad-range PCR for the diagnosis of spontaneous bacterial peritonitis: experience in a Greek tertiary care hospital. 2019 , 28, 1-5		4
187	Effects of rifaximin versus nonabsorbable disaccharides in hepatic encephalopathy. 2019, 1, 22-32		1
186	The role of gut microbiota in liver disease development and treatment. 2019 , 3, 3-18		24
185	Gut microbiota and bipolar disorder: a review of mechanisms and potential targets for adjunctive therapy. 2019 , 236, 1433-1443		24
184	Prognostic impact of toll-like receptors 2 and 4 expression on monocytes in Egyptian patients with hepatocellular carcinoma. 2019 , 67, 157-165		12
183	Immune Dysfunction and Albumin-Related Immunity in Liver Cirrhosis. 2019 , 2019, 7537649		21
182	Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis. 2019 , 10, 69		23
181	Perioperative Management and Nutritional Support in Patients With Liver and Biliary Tract Disease. 2019 , 1410-1419		
180	Bacterial DNA translocation contributes to systemic inflammation and to minor changes in the clinical outcome of liver transplantation. 2019 , 9, 835		9
179	PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal microbiota Transplantation in cirrhosis: study protocol for a single-blinded trial. 2019 , 9, e023518		21
178	Characterisation of blood microbiota in patients with liver cirrhosis. 2019 , 31, 1577-1583		14
177	THE DEGREE OF SECRETORY IMMUNOGLOBULIN A IN BURN PATIENTS WITH PROBIOTIC THERAPY. 2019 , 174-176		1
176	Ursolic Acid Improves Intestinal Damage and Bacterial Dysbiosis in Liver Fibrosis Mice. 2019 , 10, 1321		23
175	Fibrosis and the intestinal microbiome; a focus on chronic liver disease. 2019 , 49, 76-81		9
174	Renal Dysfunction in Cirrhotic Patients. 2019 , 114, 1407-1410		3
173	Increased Relative Abundance of Klebsiella pneumoniae Carbapenemase-producing Klebsiella pneumoniae Within the Gut Microbiota Is Associated With Risk of Bloodstream Infection in Long-term Acute Care Hospital Patients. 2019 , 68, 2053-2059		36
172	Interactions between Bacteriophage, Bacteria, and the Mammalian Immune System. <i>Viruses</i> , 2018 , 11,	6.2	135
171	Probiotic supplements might not be universally-effective and safe: A review. 2019 , 111, 537-547		151

170	Relationship between intestinal microbial dysbiosis and primary liver cancer. 2019, 18, 149-157	28
169	Bifidobacterium adolescentis CGMCC 15058 alleviates liver injury, enhances the intestinal barrier and modifies the gut microbiota in D-galactosamine-treated rats. 2019 , 103, 375-393	20
168	Effect of prebiotic and probiotic supplementation on circulating pro-inflammatory cytokines and urinary cortisol levels in patients with major depressive disorder: A double-blind, placebo-controlled randomized clinical trial. 2019 , 52, 596-602	21
167	Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis. 2019 , 18, 19-27	32
166	Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials. 2020 , 39, 789-819	44
165	Diagnosis and management of renal dysfunction in patients with cirrhosis. 2020 , 14, 1-7	5
164	Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives. 2020 , 50, 407-418	18
163	Association of gastric acid suppressants with the development of spontaneous bacterial peritonitis in cirrhotic patients with ascites. 2020 , 7, 139-146	
162	Role of endotoxemia in causing renal dysfunction in cirrhosis. 2020 , 68, 26-29	7
161	Bacterial Infection in Patients with Cirrhosis: DonMGet Bugged to Death. 2020 , 65, 31-37	2
160	Elevated serum procalcitonin levels and their association with the prognosis of patients with liver cirrhosis. 2020 , 32, 1222-1228	1
159	Clinical predictors and impact of bacteremia in cirrhotic patients with acute skin and skin structure infection. 2020 , 32, 251-256	1
158	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020 , 73, 842-854	108
157	Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. 2020 , 215, 107626	7
156	Current Status and Prospects of Spontaneous Peritonitis in Patients with Cirrhosis. 2020, 2020, 3743962	2
155	Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention. 2020 , 13, 1756284820942616	7
154	Crosstalk between the microbiota-gut-brain axis and depression. 2020 , 6, e04097	32
153	Secondary Sclerosing Cholangitis in Critically Ill Patients Alters the Gut-Liver Axis: A Case Control Study. 2020 , 12,	1

152	Portal Venous Flow Is Increased by Jejunal but Not Colonic Hydrogen Sulfide in a Nitric Oxide-Dependent Fashion in Rats. 2021 , 66, 2661-2668		0
151	Acute-on-Chronic Liver Failure From Chronic-Hepatitis-B, Who Is the Behind Scenes. <i>Frontiers in Microbiology</i> , 2020 , 11, 583423	5.7	7
150	Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma. 2020 , 7, 271-288		6
149	A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic Shirota in Stable Cirrhotic Patients. 2020 , 12,		12
148	BMP-9 Modulates the Hepatic Responses to LPS. <i>Cells</i> , 2020 , 9,	7.9	6
147	The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease. 2020 , 11, 1352		6
146	Nonpharmacologic Management of Hepatic Encephalopathy: An Update. <i>Clinics in Liver Disease</i> , 2020 , 24, 243-261	4.6	3
145	Betaine supplementation mitigates intestinal damage and decreases serum bacterial endotoxin in cirrhotic rats. 2020 , 12, 100179		13
144	Genetic variants of innate immunity receptors are associated with mortality in cirrhotic patients with bacterial infection. 2020 , 40, 646-653		5
143	Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction. 2020 , 65, 897-905		12
142	Antifibrotic Effects of a Barbituric Acid Derivative on Liver Fibrosis by Blocking the NF- B Signaling Pathway in Hepatic Stellate Cells. 2020 , 11, 388		6
141	Diagnostic Value of Presepsin for Bacterial Infection in Cirrhosis: A Pilot Study. 2020 , 52, 1593-1600		2
140	Gut-brain axis: A matter of concern in neuropsychiatric disorders 2021, 104, 110051		15
139	Dietary fiber regulates intestinal flora and suppresses liver and systemic inflammation to alleviate liver fibrosis in mice. 2021 , 81, 110959		12
138	Current progress of research on intestinal bacterial translocation. 2021 , 152, 104652		6
137	Active Vitamin D Treatment Attenuated Bacterial Translocation via Improving Intestinal Barriers in Cirrhotic Rats. 2021 , 65, e2000937		7
136	Impaired antibacterial response of liver sinusoidal VBVQ T cells in patients with chronic liver disease. 2021 ,		2
135	Effects of chlorpyrifos exposure on liver inflammation and intestinal flora structure in mice. 2021 , 10, 141-149		5

134	Cirrhotic Cardiomyopathy: The Interplay Between Liver and Cardiac Muscle. How Does the Cardiovascular System React When the Liver is Diseased?. 2021 , 17, 78-84		4
133	Microbiota, Inflammation, and Gut Barrier Dysfunction in HCC.		1
132	Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms. 2021 , 11, 9167		4
131	Predictive and Prognostic Value of Ascitic Fluid Mannose Binding Lectin in Patients with Spontaneous Bacterial Peritonitis. 2021 , 20, 196-200		О
130	Serum C-reactive protein and neutrophil-to-lymphocyte ratio as predictors of survival in cirrhotic patients with systemic inflammatory response syndrome and bacterial infection. 2021 , 40, 265-271		1
129	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. 2021 , 9, 427-437		3
128	Acute Decompensation and Acute-on-Chronic Liver Failure. Clinics in Liver Disease, 2021, 25, 419-430	4.6	2
127	The Role of the Microbiome in Liver Cancer. 2021 , 13,		4
126	Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions. 2021 , 10, 337-349		1
125	Sources and prevention of graft infection during long-term ex situ liver perfusion. 2021 , 23, e13623		O
124	Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites. 2021 , 5, 1507-1517		О
123	Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension. 2021 , 12, 649668		O
122	Role of circulating angiogenin levels in portal hypertension and TIPS. PLoS ONE, 2021, 16, e0256473	3.7	O
121	Targeting Gutliver Axis for Treatment of Liver Fibrosis and Portal Hypertension. 2021 , 1, 147-179		O
120	Hydrogen Sulfide Actions in the Vasculature. 2021 , 11, 2467-2488		O
119	Laboratory Tests in the Patient with Abdominal Pain. 2021, 39, 733-744		
118	Leberzirrhosen. 2021 , 383-394		
117	Modulation of intestinal flora for the treatment of hepatic encephalopathy in cirrhosis. 539-550		1

116	Regulation of the Extracellular Fluid Volume and Renal Function. 2011, 239-267		4
115	Phage Interaction with the Mammalian Immune System. 2019 , 91-122		1
114	Pathophysiology of Hepatic Encephalopathy. Clinics in Liver Disease, 2020, 24, 175-188	4.6	10
113	Increased intestinal endotoxin absorption during enteric nematode but not protozoal infections through a mast cell-mediated mechanism. 2008 , 29, 709-16		23
112	Liver cirrhosis as a real risk factor for necrotising fasciitis: a three-year population-based follow-up study. 2014 , 55, 378-82		13
111	Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. 2020 , 8, 1361-138	4	27
110	Recipient In genetic R702W NOD2 variant is associated with an increased risk of bacterial infections after orthotopic liver transplantation. <i>PLoS ONE</i> , 2013 , 8, e72617	3.7	3
109	Soluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension. <i>PLoS ONE</i> , 2013 , 8, e83341	3.7	29
108	Oxymatrine improves intestinal epithelial barrier function involving NF- B -mediated signaling pathway in CCl4-induced cirrhotic rats. <i>PLoS ONE</i> , 2014 , 9, e106082	3.7	25
107	The injured liver induces hyperimmunoglobulinemia by failing to dispose of antigens and endotoxins in the portal system. <i>PLoS ONE</i> , 2015 , 10, e0122739	3.7	10
106	Intestinal alkaline phosphatase inhibits the translocation of bacteria of gut-origin in mice with peritonitis: mechanism of action. <i>PLoS ONE</i> , 2015 , 10, e0124835	3.7	14
105	Immune Dysfunction in Cirrhosis. 2017 , 5, 50-58		57
104	Prognostic factors of liver cirrhosis mortality after a first episode of spontaneous bacterial peritonitis. A multicenter study. 2018 , 110, 94-101		2
103	Identifying Novel Targets for Treatment of Liver Fibrosis: What Can We Learn from Injured Tissues which Heal Without a Scar?. 2015 , 16, 1332-46		10
102	The Microbiota-Gut-Brain Axis in Neuropsychiatric Disorders: Pathophysiological Mechanisms and Novel Treatments. 2018 , 16, 559-573		79
101	Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of Fungi. 2019 , 14, 129-135		4
100	Involvement of ayu NOD2 in NF- B and MAPK signaling pathways: Insights into functional conservation of NOD2 in antibacterial innate immunity. 2019 , 40, 77-88		16
99	The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. 2012 , 18, 337-46		84

98	Gut flora and bacterial translocation in chronic liver disease. 2006 , 12, 1493-502	75
97	Intestinal permeability in rats with CCl4-induced portal hypertension. 2006 , 12, 479-81	12
96	Propolis reduces bacterial translocation and intestinal villus atrophy in experimental obstructive jaundice. 2007 , 13, 5226-31	8
95	Salvianolate inhibits cytokine gene expression in small intestine of cirrhotic rats. 2011 , 17, 1903-9	11
94	Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota. 2012 , 18, 6693-700	39
93	Effect of salvianolate on intestinal epithelium tight junction protein zonula occludens protein 1 in cirrhotic rats. 2012 , 18, 7040-7	8
92	Risk factors and outcome of bacterial infections in cirrhosis. 2014 , 20, 2542-54	81
91	Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. 2014 , 20, 16795-810	141
90	Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis. 2015 , 21, 11493-501	11
89	Cirrhotic cardiomyopathy. 2015 , 21, 11502-21	83
88	Dual-sugar tests of small intestinal permeability are poor predictors of bacterial infections and mortality in cirrhosis: A prospective study. 2016 , 22, 3275-84	11
87	Gastrointestinal neuromuscular apparatus: An underestimated target of gut microbiota. 2016 , 22, 9871-9879	16
86	Gut-liver axis signaling in portal hypertension. 2019 , 25, 5897-5917	35
85	[Inflammation and Hepatic Fibrosis, Then Hepatocellular Carcinoma]. 2015, 66, 320-4	9
84	Infections in Cirrhotics: Types, Microbiological Spectrum and Risk Factors B-Year Cohort Study. 2014 , 04, 105-117	2
83	Cirrhotic patients and older people. World Journal of Hepatology, 2019 , 11, 663-677	5
82	Hepatocellular carcinoma staging systems: Hong Kong liver cancer Barcelona clinic liver cancer in a Western population. <i>World Journal of Hepatology</i> , 2019 , 11, 678-688	13
81	Soluble membrane attack complex in ascites in patients with liver cirrhosis without infections. World Journal of Hepatology, 2010 , 2, 221-5	2

80	Implication of the intestinal microbiome in complications of cirrhosis. <i>World Journal of Hepatology</i> , 2016 , 8, 1128-1136	3.4	16
79	Clinical features and prognosis of spontaneous bacterial peritonitis in korean patients with liver cirrhosis: a multicenter retrospective study. <i>Gut and Liver</i> , 2009 , 3, 197-204	4.8	39
78	Complications of Liver Disease. 2022 , 443-486		O
77	Assessing the prognosis of cirrhotic patients in the intensive care unit: What we know and what we need to know better. <i>World Journal of Hepatology</i> , 2021 , 13, 1341-1350	3.4	О
76	Serum zonulin levels in patients with liver cirrhosis: Prognostic implications. <i>World Journal of Hepatology</i> , 2021 , 13, 1394-1404	3.4	1
75	[Microbiological characteristics of spontaneous bacterial peritonitis in Korea]. <i>The Korean Journal of Hepatology</i> , 2007 , 13, 304-8		2
74	Endotoxin and Cytokines in Liver and Biliary Tract Disease. 2007 , 108-124		
73	Leberzirrhosen. 2007 , 1-11		
72	Management of Hepatorenal Syndrome. 2008 , 47-57		
71	Intensivtherapie schwerer abdominalchirurgischer Krankheitsbilder. 2008 , 949-968		
7°	Erkrankungen des Gastrointestinalsystems. 2009 , 841-1057		
69	6 Portale hypertensie. 2009 , 48-63		
68	Probiotics and the Immunocompromised Host. 2009 , 219-230		
67	SIRS, Bacterial Infections, and Alterations of the Immune System. 2011 , 219-238		
66	Bacterial Translocation and Alterations of the Digestive System. 2011 , 189-218		
65	Leber-, Gallenwegs- und Pankreaserkrankungen. 2011 , 445-528		
64	Metagenomic Applications and the Potential for Understanding Chronic Liver Disease. 2011 , 277-295		
63	Spontaneous Bacterial Peritonitis in Patients with Cirrhosis and Ascites. <i>Annual Update in Intensive Care and Emergency Medicine</i> , 2011 , 559-575	0.2	

62	Features of Hormonal Disturbances in Cirrhotic Patients with Hepatic Encephalopathy. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2012 , 2, 84-89	1.6	0
61	Portal Hypertensive Bleeding. 2012 , 145-163		
60	Intensive Care Management of Children with Liver Failure. 2014 , 463-481		
59	Cirrhosis. 2014, 181-187		
58	Antibiotic Prophylaxis in Acute Variceal Hemorrhage. 2014 , 123-133		
57	Pre-primary and Primary Prophylaxis of Variceal Hemorrhage. 2014 , 75-96		
56	Liver failure. 2014 , 501-519.e3		
55	Diagnosis of spontaneous bacterial peritonitis. <i>The Egyptian Journal of Internal Medicine</i> , 2014 , 26, 53-59	0.5	1
54	Unusual CAPDCitrobacter freundiiPeritonitis Complicated by a Fungal Infection, Identified by 16s Ribosomal RNA Gene Sequencing. <i>Korean Journal of Medicine</i> , 2015 , 88, 593	0.5	1
53	SMALL INTESTINE BACTERIAL OVERGROWTH IN PATIENTS WITH FAILURE OF THE VALVE BAUHINIAS AND AFTER ITS SURGICAL TREATMENTS (THE FIRST RESULTS). <i>Bulletin of Siberian</i> <i>Medicine</i> , 2015 , 14, 12-19	0.4	
52	Ascites and Its Complications. 2087-2106		
51	EVALUATION OF PROCALCITONIN AND C-REACTIVE PROTEIN IN PATIENTS OF CIRRHOSIS OF LIVER WITH SEPSIS- A CROSS-SECTIONAL STUDY. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2017 , 4, 2853-2857	О	
50	Leberzirrhosen. 2018 , 446-456		
49	Initial choice of antibiotic in recurrent spontaneous bacterial peritonitis: A retrospective study. <i>International Journal of Critical Illness and Injury Science</i> , 2019 , 9, 187-190	0.7	
48	Intestinal mucus and gut-vascular barrier: FxR-modulated entry sites for pathological bacterial translocation in liver cirrhosis.		
47	IMMUNE MECHANISMS FOR THE DEVELOPMENT OF HEPATORENAL SYNDROME IN LIVER CIRRHOSIS. 2020 , 7-19		1
46	Cirrhosis and ascites. 2020 , 3058-3068		
45	Hepatic Cirrhosis: Diagnostic and Prognosis in Internal Medicine. <i>Open Journal of Internal Medicine</i> , 2020 , 10, 171-180	0.2	

New role of bile acid metabolism in intestinal bacteria translocation. 83-91

43	Pathogenesis of Liver Injury and Hepatic Failure. 2021 , 105-166		2
42	Study of the Etiological Spectrum of Spontaneous Bacterial Peritonitis in a Group of Patients Suffering from Liver Cirrhosis. <i>Current Health Sciences Journal</i> , 2016 , 42, 365-371	0.3	1
41	A retrospective study of bacterial infections in cirrhosis. <i>Mdica</i> , 2011 , 6, 185-92		3
40	Spontaneous bacterial peritonitis in extrahepatic portal venous obstruction. <i>Annals of Gastroenterology</i> , 2013 , 26, 363-364	2.2	3
39	Beta-blockers in liver cirrhosis. <i>Annals of Gastroenterology</i> , 2014 , 27, 20-26	2.2	24
38	C-reactive protein and bacterial infection in cirrhosis. <i>Annals of Gastroenterology</i> , 2014 , 27, 113-120	2.2	33
37	Bacteriologic study of cirrhotic patients with non-neutrocytic ascites. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2014 , 7, 224-9	1.2	3
36	Risk factors of cellulitis in cirrhosis and antibiotic prophylaxis in preventing recurrence. <i>Annals of Gastroenterology</i> , 2014 , 27, 374-379	2.2	12
35	Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. International Journal of Clinical and Experimental Pathology, 2015, 8, 5153-60	1.4	60
34	Diagnostic Accuracy of Ascites Fluid Gross Appearance in Detection of Spontaneous Bacterial Peritonitis. <i>Emergency</i> , 2014 , 2, 138-40		4
33	Systemic levels of human Edefensin 1 are elevated in patients with cirrhosis. <i>Annals of Gastroenterology</i> , 2016 , 29, 63-70	2.2	15
32	Next- and Third-Generation Sequencing Outperforms Culture-Based Methods in the Diagnosis of Ascitic Fluid Bacterial Infections of ICU Patients. <i>Cells</i> , 2021 , 10,	7.9	0
31	Gut-derived systemic inflammation as a driver of depression in chronic liver disease. <i>Journal of Hepatology</i> , 2021 ,	13.4	5
30	Polymyxin B engineered polystyrene-divinylbenzene microspheres for the adsorption of bilirubin and endotoxin <i>RSC Advances</i> , 2021 , 11, 39978-39984	3.7	3
29	Human Amnion-Derived Mesenchymal Stromal Cells: A New Potential Treatment for Carbapenem-Resistant in Decompensated Cirrhosis <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	О
28	The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial <i>PLoS ONE</i> , 2022 , 17, e0264278	3.7	0
27	Oxidative Stress and Gut Microbiome in Inflammatory Skin Diseases <i>Frontiers in Cell and Developmental Biology</i> , 2022 , 10, 849985	5.7	2

26	Hepatorenal Syndrome: Pathophysiology Clinics in Liver Disease, 2022, 26, 165-179	4.6	О
25	Active Surveillance Cultures and Procalcitonin in Combination With Clinical Data to Guide Empirical Antimicrobial Therapy in Hospitalized Medical Patients With Sepsis <i>Frontiers in Microbiology</i> , 2022 , 13, 797932	5.7	O
24	Antibiotics and Liver Cirrhosis: What the Physicians Need to Know Antibiotics, 2021, 11,	4.9	4
23	Data_Sheet_1.docx. 2020 ,		
22	Image_1.pdf. 2019 ,		
21	Image_2.pdf. 2019 ,		
20	Table_1.DOCX. 2019 ,		
19	Presentation_1.pdf. 2019,		
18	Table_1.docx. 2019 ,		
17	as a causative agent of spontaneous bacterial peritonitis BMJ Case Reports, 2022, 15,	0.9	O
16	Advances in the Management of Renal Dysfunction in Patients With Cirrhosis <i>Gastroenterology and Hepatology</i> , 2021 , 17, 211-220	0.7	
15	Circulating MicroRNAs as a Tool for Diagnosis of Liver Disease Progression in People Living with HIV-1. <i>Viruses</i> , 2022 , 14, 1118	6.2	O
14	Probiotics and gut-brain axis modulation. 2022 , 373-410		
13	Plasma Phage Load is Positively Related to the Immune Checkpoints in Patients Living with Human Immunodeficiency Virus. <i>Current HIV Research</i> , 2022 , 20,	1.3	
12	Influence of Gut[liver Axis on Portal Hypertension in Advanced Chronic Liver Disease: The Gut Microbiome as a New Protagonist in Therapeutic Management. 2022 , 13, 539-555		
11	Structural and compositional segregation of the gut microbiota in HCV and liver cirrhotic patients: A clinical pilot study. 2022 , 171, 105739		O
10	Spontaneous Bacterial Peritonitis in Decompensated Liver Cirrhosis Literature Review. 2022 , 2, 214-2	232	О
9	Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort. 2022 , 101, e30097		Ο

8	Concept of Further Decompensation and Recompensation. 2022, 523-535	0
7	Altered Gut Microbiota in Hepatocellular Carcinoma: Insights into the Pathogenic Mechanism and Preclinical to Clinical Findings.	1
6	Prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria. Alterations in ultrasonographic parameters of both left and right ventricles before and after stress.	O
5	Bacteremia (Sepsis), Hepatorenal Syndrome, and Serum Creatinine Levels Rather than Types or Microbial Patterns Predicted the Short-Term Survival of Cirrhotic Patients Complicated with Spontaneous Bacterial Peritonitis. 2023 , 13, 94	O
4	Emerging Therapeutic Targets for Portal Hypertension. 2023 , 22, 51-66	0
3	Emerging Therapeutic Targets for Portal Hypertension. 2023 , 22, 51-66 Clinical and pathophysiological understanding of the hepatorenal syndrome: Still wrong or still not exactly right?. 11, 1261-1266	0
·	Clinical and pathophysiological understanding of the hepatorenal syndrome: Still wrong or still not	